Showing 3 posts of 3 posts found.


AstraZeneca jettisons two heart drugs to Cheplapharm in $400m deal

October 30, 2020
Manufacturing and Production, Medical Communications, Sales and Marketing AstraZeneca, Cheplapharm

AstraZeneca is set to sell the rights to its AT1 subtype angiotensin II receptor antagonist Atacand (candesartan cilexetil) and Atacand …


Takeda to sell another non-core portfolio for $260 million to Cheplapharm

September 8, 2020
Manufacturing and Production, Sales and Marketing Cheplapharm, Takeda, pharma

Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an …


AstraZeneca jettisons European heart drug rights for $210m

July 24, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Atacand, Cheplapharm, blood pressure, heart failure, pharma

AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment …

Latest content